Sprenger, Thilo

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Homayonfaur, K."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Yildirim, Muejdat"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:55:28Z"],["dc.date.available","2018-11-07T08:55:28Z"],["dc.date.issued","2011"],["dc.format.extent","46"],["dc.identifier.isi","000291236200125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22909"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","17th Annual Meeting of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","A lack of down-regulation of survivin after neoadjuvant Chemoradiotherapy for Rectal cancer with distant metastasis and Reduced survival rate linked"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","738"],["dc.bibliographiccitation.issue","4, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.lastpage","738"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Sauer, Rolf"],["dc.contributor.author","Fokas, Emmanouil"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Rödel, Claus"],["dc.contributor.author","Ghadimi, Michael"],["dc.date.accessioned","2020-12-10T18:41:36Z"],["dc.date.available","2020-12-10T18:41:36Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1200/JCO.2018.36.4_suppl.738"],["dc.identifier.eissn","1527-7755"],["dc.identifier.issn","0732-183X"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77623"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","The influence of hospital and surgeon volume on survival and local control in rectal cancer: Long-term results of the CAO/ARO/AIO-94 trial."],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","27"],["dc.bibliographiccitation.journal","World Journal of Surgical Oncology"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Jung, Klaus"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Ghadimi, B. Michael"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:44:09Z"],["dc.date.available","2018-11-07T08:44:09Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Response to preoperative radiochemotherapy (RCT) in patients with locally advanced rectal cancer is very heterogeneous. Pathologic complete response (pCR) is accompanied by a favorable outcome. However, most patients show incomplete response. The aim of this investigation was to find indications for risk stratification in the group of intermediate responders to RCT. Methods: From a prospective database of 496 patients with rectal adenocarcinoma, 107 patients with stage II/III cancers and intermediate response to preoperative 5-FU based RCT (ypT2/3 and TRG 2/3), treated within the German Rectal Cancer Trials were studied. Surgical treatment comprised curative (R0) total mesorectal excision (TME) in all cases. In 95 patients available for statistical analyses, residual transmural infiltration of the mesorectal compartment, nodal involvement and histolologic tumor grading were investigated for their prognostic impact on disease-free (DFS) and overall survival ( OS). Results: Residual tumor transgression into the mesorectal compartment (ypT3) did not influence DFS and OS rates ( p = 0.619, p = 0.602, respectively). Nodal involvement after preoperative RCT (ypN1/2) turned out to be a valid prognostic factor with decreased DFS and OS (p = 0.0463, p = 0.0236, respectively). Persistent tumor infiltration of the mesorectum ( ypT3) and histologic tumor grading of residual tumor cell clusters were strongly correlated with lymph node metastases after neoadjuvant treatment (p < 0.001). Conclusions: Advanced transmural tumor invasion after RCT does not affect prognosis when curative ( R0) resection is achievable. Residual nodal status is the most important predictor of individual outcome in intermediate responders to preoperative RCT. Furthermore, ypT stage and tumor grading turn out to be additional auxiliary factors. Future clinical trials for risk-adapted adjuvant therapy should be based on a synopsis of clinicopathologic parameters."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft"],["dc.identifier.doi","10.1186/1477-7819-8-27"],["dc.identifier.isi","000277431000001"],["dc.identifier.pmid","20388220"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5680"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20132"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1477-7819"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: Do we have indications for individual risk stratification?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:45:05Z"],["dc.date.available","2018-11-07T09:45:05Z"],["dc.date.issued","2014"],["dc.identifier.isi","000333682100536"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/34538"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","Gastrointestinal Cancers Symposium"],["dc.relation.eventlocation","San Francisco, CA"],["dc.title","Residual rectal cancer after preoperative radiochemotherapy (ypT1-2): An indication for local excision instead of radical surgery?"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1283"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","1289"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Beissbarth, Tim"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gauss, Korbinian"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Wolff, Hendrik"],["dc.contributor.author","Scheel, Andreas H."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2021-06-01T10:47:01Z"],["dc.date.available","2021-06-01T10:47:01Z"],["dc.date.issued","2013"],["dc.identifier.doi","10.1097/PAS.0b013e3182886ced"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85449"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0147-5185"],["dc.title","Lymph Node Metastases in Rectal Cancer After Preoperative Radiochemotherapy"],["dc.title.alternative","Impact of Intramesorectal Distribution and Residual Micrometastatic Involvement"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Onkologie"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Quack, H."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Binder, L."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Lorenzen, Stephan"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:19:02Z"],["dc.date.available","2018-11-07T09:19:02Z"],["dc.date.issued","2013"],["dc.format.extent","73"],["dc.identifier.isi","000326360900167"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/28546"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.relation.issn","1423-0240"],["dc.relation.issn","0378-584X"],["dc.title","5-FU dose monitoring under neoadjuvant radiochemotherapy and adjuvant chemotherapy for locally advanced rectal cancer"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","621"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","The Oncologist"],["dc.bibliographiccitation.lastpage","631"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Schirmer, Markus Anton"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rave-Fränk, Margret"],["dc.contributor.author","Hennies, Steffen"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:01:50Z"],["dc.date.available","2018-11-07T09:01:50Z"],["dc.date.issued","2011"],["dc.description.abstract","Patients with locally advanced rectal cancer (cUICC stages II/III) are typically treated with preoperative 5-fluorouracil-based (5-FU-based) radiochemotherapy (RCT). However, trials are currently being conducted to improve the complete remission rates and the systemic control by combining 5-FU with oxaliplatin. The primary objective was to identify the subgroups of rectal cancer patients who were at risk for high-grade toxicity. All 196 patients who were included in the present study were treated with 50.4 Gy and chemotherapy that included either 5-FU (n = 115) or 5-FU + oxaliplatin (n + 81). The preoperative RCT was followed by a total mesorectal excision and adjuvant chemotherapy. Acute toxicity was monitored weekly and a toxicity grade >= 3 (Common Toxicity Criteria) for a skin reaction, cystitis, proctitis, or enteritis was defined as high-grade acute organ toxicity. After RCT with 5-FU + oxaliplatin, complete tumor remission was achieved in 13.6% of the patients and in 11.3% after RCT with 5-FU alone. Complete irradiation dosages of 50.4 Gy were given to 99% (5-FU) and 95% (5-FU + oxaliplatin) of the patients. Concomitant chemotherapy was fully administered in 95% of the patients treated with 5-FU compared with the 84% of patients treated with 5-FU + oxaliplatin. A significantly higher proportion of acute organ toxicity was found in the patients who were treated with 5-FU + oxaliplatin compared with those who were treated with 5-FU. Additionally, women with a low body mass index were at the highest risk for acute organ toxicity. These results suggest that there are basic clinical parameters, such as gender and body mass index, that may be potential markers for generating individual risk profiles of RCT-induced toxicity. The Oncologist 2011;16:621-631"],["dc.identifier.doi","10.1634/theoncologist.2010-0414"],["dc.identifier.isi","000290661900012"],["dc.identifier.pmid","21558132"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24528"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Alphamed Press"],["dc.relation.issn","1083-7159"],["dc.title","Gender-Specific Acute Organ Toxicity during Intensified Preoperative Radiochemotherapy for Rectal Cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","522"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.lastpage","531"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Styczen, Hanna"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Gaedcke, Jochen"],["dc.contributor.author","Kitz, Julia"],["dc.contributor.author","Talaulicar, Recca"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Middel, Peter"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Rüschoff, Josef R."],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T09:26:46Z"],["dc.date.available","2018-11-07T09:26:46Z"],["dc.date.issued","2013"],["dc.description.abstract","In patients with advanced rectal cancer (cUICC II and III) multimodality therapy resulted in better long-term local tumor control. Ongoing clinical trials are focusing on therapy intensification to improve disease-free (DFS) and cancer-specific survival (CSS), the integration of biomarkers for prediction of individual recurrence risk, and the identification of new targets. In this context, we investigated HER-2, a member of the epidermal growth factor receptor family, whose expression pattern and role was unclear in rectal cancer. A total of 264 patients (192 male, 72 female; median age 64 y) received standardized multidisciplinary treatment according to protocols of phase II/III trials of the German Rectal Cancer Study Group. HER-2 status was determined in pretherapeutic biopsies and resection specimens using immunohistochemistry scoring and detection of silver in situ hybridization amplification. Tumors with an immunohistochemistry score of 3(+) or silver in situ hybridization ratios of >= 2.0 were classified HER-2 positive; these results were correlated with clinicopathologic parameters [eg, resection (R) status, nodal status ((y)pN)], DFS, and CSS. Positive HER-2 status was found in 12.4% of biopsies and in 26.7% of resected specimens. With a median follow-up of 46.5 months, patients with HER-2 positivity showed in trend a better DFS (P = 0.1) and a benefit in CSS (P = 0.03). The 5-year survival rate was 96.0% (HER-2 positive) versus 80.0% (HER-2 negative). In univariate and multivariate analyses, HER-2 was an independent predictor for CSS (0.02) along with the (y)pN status (P < 0.00001) and R status (P = 0.011). HER-2 amplification is detectable in a relevant proportion (26.7%) of rectal cancer patients. For the development of innovative new therapies, HER-2 may represent a promising target and should be further assessed within prospective clinical trials."],["dc.description.sponsorship","Deutsche Forschungsgemeinschaft [KFO 179-2]"],["dc.identifier.doi","10.1097/PAS.0b013e318272ff4d"],["dc.identifier.isi","000316184000006"],["dc.identifier.pmid","23282976"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30374"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1532-0979"],["dc.relation.issn","0147-5185"],["dc.title","Frequency of HER-2 Positivity in Rectal Cancer and Prognosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","American Journal of Surgical Pathology"],["dc.bibliographiccitation.volume","33"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Langer, Claus"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Liersch, Torsten"],["dc.date.accessioned","2018-11-07T08:27:52Z"],["dc.date.available","2018-11-07T08:27:52Z"],["dc.date.issued","2009"],["dc.format.extent","1107"],["dc.identifier.isi","000268043400019"],["dc.identifier.pmid","19390426"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/16297"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1532-0979"],["dc.relation.issn","0147-5185"],["dc.title","Comment on \"Lymph Nodes After Preoperative Chemoradiotherapy for Rectal Carcinoma: Number, Status, and Impact on Survival\""],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]